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Small cell lung cancer (SCLC) has recently been subcategorized into neuroen-
docrine (NE)-high and NE-low subtypes showing ‘immune desert’ and ‘im-
mune oasis’ phenotypes, respectively. Here, we aimed to characterize the
tumor microenvironment according to immune checkpoints and NE sub-
types in human SCLC tissue samples at the protein level. In this cross-sec-
tional study, we included 32 primary tumors and matched lymph node (LN)
metastases of resected early-stage, histologically confirmed SCLC patients,
which were previously clustered into NE subtypes using NE-associated key
RNA genes. Immunohistochemistry (IHC) was performed on formalin-fixed
paraffin-embedded TMAs with antibodies against CD45, CD3, CD8,
MHCII, TIM3, immune checkpoint poliovirus receptor (PVR), and indolea-
mine 2,3-dioxygenase (IDO). The stroma was significantly more infiltrated
by immune cells both in primary tumors and in LN metastases compared to
tumor nests. Immune cell (CD45+ cell) density was significantly higher in
tumor nests (P = 0.019), with increased CD8+ effector T-cell infiltration
(P = 0.003) in NE-low vs NE-high tumors. The expression of IDO was con-
firmed on stromal and endothelial cells and was positively correlated with
higher immune cell density both in primary tumors and in LN metastases,
regardless of the NE pattern. Expression of IDO and PVR in tumor nests
was significantly higher in NE-low primary tumors (vs NE-high, P < 0.05).
We also found significantly higher MHC II expression by malignant cells in
NE-low (vs NE-high, P = 0.004) tumors. TIM3 expression was significantly
increased in NE-low (vs NE-high, P < 0.05) tumors and in LN metastases
(vs primary tumors, P < 0.05). To our knowledge, this is the first human
study that demonstrates in situ that NE-low SCLCs are associated with
increased immune cell infiltration compared to NE-high tumors. PVR, IDO,
Abbreviations
APC, antigen-presenting cell; DC, dendritic cell; FFPE, formalin-fixed paraffin-embedded; IDO, indoleamine 2,3-dioxygenase; LN, lymph
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MHCII, and TIM3 are emerging checkpoints in SCLC, with increased
expression in the NE-low subtype, providing key insight for further prospec-
tive studies on potential biomarkers and targets for SCLC immunotherapies.
1. Introduction
Very recently, substantial milestones have been
achieved in the understanding of small cell lung cancer
(SCLC) biology. Two recent randomized trials com-
paring etoposide-platinum doublet therapy alone to
the same therapy plus a checkpoint inhibitor (ate-
zolizumab or durvalumab) as first-line therapy showed
significant increases in progression-free survival (PFS;
4.3–5.2 month), response rate, and overall survival
(OS; 12.3–13 vs 10.3 months) with the immunotherapy
[1,2]. However, these benefits are limited, and
biomarkers, such as smoking status, tumor mutation
burden (TMB), and programmed cell death-ligand 1
(PD-L1) expression, did not predict outcome. The lack
of a biomarker and the limited benefit for a small por-
tion of patients points toward the idea that SCLC
might be associated with a different immunological
microenvironment [3, 4]. Furthermore, a lack of tumor
tissue availability due to disease aggressiveness limits
our understanding of crucial immunological mecha-
nisms, including immune cell infiltration, intertumor
and intratumor heterogeneity, and is one reason
behind the long-term failure of immunotherapies.
Moreover, in many patients, lymph node (LN) metas-
tases are the primary motivators for rapid disease pro-
gression, and their immunological environment is far
less understood.
Small cell lung cancer is no longer considered as a
single-disease entity, and subtypes are defined by dis-
tinct RNA gene expression profiles which can be clas-
sified into neuroendocrine (NE)-high and NE-low
tumors, which may have different immunogenicity [5].
NE-high is characterized by decreased immune cell
infiltration defined as a cold or ‘immune desert’ pheno-
type, based on low levels of immune cell-related RNA
expression. In contrast, NE-low was associated with
tumors with increased immunogenicity, in other words
‘hot’ or ‘immune oasis’ phenotype [4–7]. Consequently,
NE-low SCLC patients may more likely respond to
immunotherapies [9,10]. The immune infiltrate is com-
prised of innate and adaptive immune cells, whose
populations are heterogeneous across tumor types and
patients and include nonspecific immune cell types,
such as macrophages, neutrophil granulocytes, den-
dritic, mast and natural killer (NK) cells, or effector
cells of specific immunity, like B- and CD3+ T cells
(CD4+ T helper, CD8+ cytotoxic T, and regulatory T
[Treg] cells), localized in tumor nests, or adjacent
tumor stroma [11]. A high number of dendritic cells
(DCs), NK cells, B cells, and CD8+ T cells were associ-
ated with improved prognosis, while the presence of
Treg cells correlates with decreased survival time in
NSCLC [12,13]. The invasion of tumor nests by
immune cells confers better OS in lung cancer and
other malignancies [14,15].
In addition to the presence of tumor-infiltrating
immune cells, the expression of specific immune check-
points is also a crucial immune-suppressing factor in
many cancers. Poliovirus receptor (PVR), an impor-
tant factor in the SCLC microenvironment, is an adhe-
sion molecule involved in cell motility, as well as NK
cell and T-cell-mediated immunity. PVR is relatively
absent in normal tissues, but regularly overexpressed
in malignancies promoting tumor cell invasion and
migration [16]. PVR expression was detected at low
levels in multiple cell types of epithelial origin and
overexpressed in cancers of epithelial and neural ori-
gins [17–19]. PVR was also proved to play a crucial
role in oncoimmunity, as a ligand of coinhibitory
receptor TIGIT and CD96 on NK and T cells [20].
Recently, it was reported that PVR is highly expressed
in SCLC cell lines with minimal expression observed
on immune cells in the tumor microenvironment [21].
Indoleamine-2,3-dioxygenase 1 (IDO) is a key factor
in defining cancer immunogenicity [22] and is a cytoso-
lic enzyme catalyzing the first and rate-limiting step of
tryptophan (Trp) catabolism. Multiple studies revealed
that the accumulation of Trp metabolites promotes the
differentiation of Treg cells and induces the apoptosis
of effector T cells with consequent immunosuppression
[23,24]. IDO is overexpressed in many tumor types
exploiting immunosuppressive mechanisms to promote
their spread and survival [25].
While antigen-presenting cells (APCs) constitutively
express major histocompatibility complex (MHC) class
II; many other cell types, including malignant cells, are
also capable of expressing MHC II [26]. Tumor-speci-
fic expression of the MHC II molecule was shown to
increase tumor recognition by immune cells and conse-
quently may play a pivotal role in immunotherapy
[27]. Of note, MHC II expression by tumor cells has
been associated with improved prognosis and response
to immunotherapy in breast cancer [28] and melanoma
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[29]. Lymphocyte exhaustion is a common cause of
anergy in antitumor immune responses [30]. TIM-3,
also known as HAVCR2, is a negative regulatory
immune checkpoint and is detected in different types
of immune cells, including T and B cells, macrophages,
DCs, NK, and mast cells [31]. Its negative role in anti-
cancer immunity was shown in mediating T-cell
exhaustion [32,33], where T-cell immunoglobulin and
mucin domain-containing protein 3 (TIM3)+ CD8+ T
cells exhibited impaired Stat5 and p38 signaling.
This study focuses on the evaluation and quantifica-
tion of immune cell infiltration by localization and dis-
tribution patterns in the stroma and tumor nests
according to SCLC NE subtypes. In addition, SCLC
tumors were evaluated for the expression of MHC II,
emerging immune checkpoints PVR, IDO, and lympho-
cyte exhaustion markers, including TIM3 to allow for
new trials of immune therapy in these SCLC subsets.
2. Materials and methods
2.1. Ethics statement
Research was conducted in accordance with the guide-
lines of the Helsinki Declaration of the World Medical
Association. The approval of the Hungarian Scientific
and Research Ethics Committee of the Medical
Research Council, (ETTTUKEB-7214-1/2016/EKU)
was obtained and waived the need for individual
informed consent for this study. After the collection of
clinical data, patient identifiers were removed so that
patients may not be identified either directly or indi-
rectly.
2.2. Study population
A total of 32 histologically confirmed early-stage
SCLC patients with available primary tumor tissue
and matched LN metastases were included in our
study as previously described [34]. All patients under-
went surgical resection in the period from 1978 to
2013 at the National Koranyi Institute of Pul-
monology. Formalin-fixed, paraffin-embedded (FFPE)
tissue samples from primary tumors and LN metas-
tases were obtained at the time of lung resection sur-
gery. Clinicopathological characteristics were described
earlier [34].
2.3. Tissue processing
Small cell lung cancer patient tumors were obtained
by surgical resection and were fixed and processed
into paraffin blocks. Tissue microarray (TMA) con-
struction from FFPE blocks was performed as previ-
ously described [35]. Briefly, 4-micron sections from
each tissue block were prepared using a HM-315
microtome (Microm, Boise, ID, USA) and placed on
charged glass slides (Colorfrost Plus, #22-230-890;
Fisher, Racine, WI, USA). Slides were stained for
H&E on an automated Tissue-Tek Prisma staining
platform (Sukura, Osaka, Japan). H&E slides were
reviewed by a laboratory pathologist for tumor area
and the tumor border marked. Marked-stained sec-
tions were used to guide the technician as to the
location for punch tissue removal. Two 1-mm
punches of tissue were taken from each donor tissue
block for primary tumors, and one 1-mm punch
from LN metastases blocks and seated into a recipi-
ent paraffin block in a positionally encoded array
format (MP10 1.0 mm tissue punch on a manual
TMA instrument; Beecher Instruments, Sun Prairie,
WI, USA).
2.4. Molecular analysis
RNA expression data from primary and LN FFPE
tumor tissue samples were obtained using the HTG
EdgeSeq Targeted Oncology Biomarker Panel as previ-
ously described [34]. Tumors were clustered into NE-
low (n = 21) and NE-high (n = 43) subtypes according
to their NE gene expression patterns as previously
reported [34].
2.5. Immunohistochemistry
Four-micron-thick sections were cut from FFPE TMA
blocks for IHC staining. Slides were stained on a Leica
Bond RX autostainer using rabbit monoclonal anti-
body for IDO (#86630), CD45 (#13917), CD3
(#85061), CD8 (#8112), MHC II (#68258), PD-L1
(13684S), and PVR (#81254) from Cell Signaling
(Danvers, MA, USA) and diluted 1 : 200 with Cell
Signaling antibody diluent (#8112) prior to staining.
Antibodies TIM3 (PA0360), LAG3 (PA0300), and
PD-1 (PA0216) were from Leica Biosystems (Wetzlar,
Germany) diluted 1 : 200 with Leica antibody diluent.
Slides were stained using the Bond Polymer Refine
Detection kit (#DS9800) with Leica IHC Protocol F
and exposed to epitope retrieval 1 (low pH) for
20 min. Following staining, slides were cleared and
dehydrated on an automated Tissue-Tek Prisma plat-
form and cover-slipped using a Tissue-Tek Film cover
slipper. The detection of protein expression was opti-
mized in human tonsil and thymus tissue as a positive
control.
1949Molecular Oncology 14 (2020) 1947–1965 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
D. Dora et al. Immune microenvironment in NE-high vs NE-low SCLC
2.6. Cell counting and morphometry
Images of TMA sections were captured via a BX53
upright Olympus microscope and a DP74 color CMOS
camera with 109 magnification objectives in 20MP
resolution for scoring and cell counting and with 209
magnification for representative images from tumor
tissues. Morphometry based on stromal and tumor
nest area measurements was performed by OLYMPUS
CELLSENS DIMENSIONS Software package by manual
annotation of measured areas, as previously described
[36]. In the case of primary tumors, for one patient,
two different TMA specimens were analyzed (A and
B), retrieved from different regions of resected tumors.
In the case of LN metastases, one TMA specimen was
prepared from each LN sample. From all TMA
blocks, two separate four-micron-thick sections (with a
minimum of 100-lm distance in Z between them) were
quantified using high resolution (20MP) 109 magnifi-
cation images. Positive cells for immune markers
CD45, CD3, CD8, IDO, and TIM3 were identified by
the presence of brown DAB precipitation around
hematoxylin-stained cell nuclei by a systematic quanti-
tative method based on software-assisted, manual cell
counting by two independent observers using the cell
counter plug-in of IMAGEJ software [37]. PVR and
MHCII expression was assessed semiquantitatively,
where 0 = negative, 1 = low, 2 = moderate, 3 = strong,
4 = very strong expression scores were given for each
specimen. Immune cells and tumor cells regarding
MHC II—positivity were identified according to
nuclear and cellular morphology. Quantification of
IDO and TIM3 expression was based on positive cell
numbers in stroma and tumor nests in the whole visual
field (109 magnification) of two separate sections of
one TMA core. No DAB signs without the character-
istic cellular shape or without the co-presence of
nuclear staining were included in the calculations.
Stromal and tumor nest total areas were measured
using the area measurement tool in the OLYMPUS CELL-
SENS DIMENSIONS software package. Square micrometers
(lm2) were converted to square millimeters (mm2) for
calculation of cell density parameters in statistical
analyses. Regions of apoptosis, necrosis, and damage
or disruptions in the sections were not included in the
measurements. Results (cell numbers and areas) from
separate sections of the same TMA punches were aver-
aged before statistical assessment.
2.7. Statistical methods
First, we used the Kolmogorov–Smirnov test to deter-
mine which variable follows a normal distribution,
where CD45, CD3, CD8, IDO, PVR, TIM3, and MHC
II do not, but CD3/CD45 and CD8/CD3 cell density
ratios followed a normal distribution. Next, we used the
Wilcoxon matched-pairs signed ranks test to test
whether core A and B population mean rank differ.
However, we found no significant differences regarding
any variables. Accordingly, we used average core A and
B values in further statistical analyses. We used the
Mann–Whitney U-test to compare CD45, CD3, CD8,
IDO, and TIM3 expressions between primary tumors
and LN metastases and between NE-low and NE-high
subtypes in the stroma or tumor compartments. To
compare NE-low and NE-high subtypes in the case of
ordinal variables, PVR and MHCII, we used Mann–
Whitney U-test. P-values < 0.05 indicate the significance
and all P-values were two-sided. We found significant
differences for all variables between tumor core A and
stroma core A, or between tumor core B and stroma
core B (Wilcoxon matched-pairs signed ranks test).
Accordingly, Wilcoxon matched-pair test was further
used to compare CD45, CD3, and CD8 expression
between stroma and tumor nests in primary tumors or
LN metastases. We used unpaired Student’s t-test to
analyze variables with normal distribution. Spearman’s
rank correlation was used for continuous variables such
as CD45, CD3, CD8, and IDO and Kendall’s Tau-b
(Kendall rank correlation coefficient) for ordinal vari-
able, PVR. The correlation coefficient (r) can vary
between 1 and 1. We define no correlation
(0 < r < 0.2), weak positive correlation (0.2 < r < 0.4),
moderate positive correlation (0.4 < r < 0.6), and
strong positive correlation (0.6 < r < 1). All statistical
analyses were implemented using the PASW STATISTICS
22.0 package (SPSS Inc., Chicago, IL, USA).
3. Results
In our study, we aimed to reveal the precise distribution
pattern of immune cells in situ on SCLC tissue samples.
For this, we performed IHC on serial sections of FFPE
TMA samples and demarcated the histological compart-
ments of tumor stroma (stroma) and epithelial tumor
nests (tumor) with consequent software-aided area mea-
surement, followed by cell counting in every sample.
First, we analyzed the histological distribution of
immune cells in stroma vs tumor nests in representative
samples shown in Fig. 1. CD45 immunolabeling identi-
fies a high number of immune cells in the stroma
(Fig 1A,B), but a limited number of cells in epithelial
tumor nests (Fig. 1C,D). Borders of fibrous stromal
strands and tumor nests are shown with dashed lines,
and immune cells inside tumor nests are indicated with
arrowheads in Fig. 1C,D on representative TMA
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sections. CD3 labels all mature T-cell populations of
round cellular morphology (Fig. 1E,F), whereas CD8
represents the general marker for cytotoxic (effector) T
cells (Fig. 1G,H). Successive sections from the same pri-
mary tumor sample of SCLC patient show the expres-
sion of CD45 (Fig. 1I), CD3 (Fig. 1I0) and CD8 (Fig 1I
″) on consecutively narrower cell populations (immune
cells, T cells, CD8+ T cells) in the same area of the TMA
specimen. Based on our in situ HE-stained sections, the
stroma and tumor area ratio were similar in primary
tumors and LN metastases (Fig. S1A), and there were
no statistically significant differences according to NE
subtypes (Fig. S1B).
3.1. Immune cell distribution in primary tumors
and lymph node metastases
Next, we compared the presence of immune cells
according to anatomic localization. Immune cell marker
expression according to primary tumors vs LN metas-
tases is shown in Fig. 2. We found that CD45+
(Fig. 2A,B), CD3+ (Fig. 2E,F), and CD8+ (Fig. 2I,J)
immune cell density was significantly higher in the
stroma of LN metastases compared to primary tumors,
but there was no significant difference in the case of
tumor nests (tumor). Moreover, the stroma of primary
tumors were significantly more infiltrated by major
immune cells vs tumor nests, in primary tumors (Fig. 2,
G,K; P < 0,001) and in LN metastases (Fig. 2D,H,L;
P < 0,001). Figure S2 shows the relative distribution of
major immune cells in stroma vs tumor nests, according
to primary tumors and LN metastases.
3.2. Immune cell distribution according to NE
subtypes and tumor compartments
Table S1 shows the key tumor microenvironmental
protein expression data according to NE-low vs NE-
Fig. 1. Histological localization of major immune cells in SCLC in representative tissue samples. Qualitative in situ IHC data on the
histological distribution of immune cells show high immune cell density in the stroma and a low number of labeled cells in tumor nests (A,
B magnified image) stained with anti-CD45 antibody and hematoxylin (ID of samples in italics). Infiltration of CD45+ immune cells in tumor
nests can be low (A, B) or moderate (C, D), where dashed line signs the border of stroma and epithelial tumor nests (C, D) and arrowheads
show immune cells inside tumor nests (D). Sections of whole TMA specimens stained with anti-CD3 and anti-CD8 antibodies show the
presence of CD3+ T cells (E, F) and CD8+ cytotoxic T cells (G, H) in low (E, G) and high (F, H) magnification images in tumor stroma and
sparsely in tumor nests. High magnification images of consecutive sections from the same TMA specimen and region of interest show
CD45 (I), CD3 (I0) and CD8 (I″) labeling of tumor-infiltrating immune cells.
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high SCLC subtypes. In primary tumors, we found a
significantly increased stromal density of CD45+ cells
(Fig. 3A; P = 0.02), CD3+ cells (Fig. 3E; P = 0.022),
and CD8+ cells (Fig. 3I; P = 0.006) in NE-low com-
pared to NE-high subtypes. Similarly, there were sig-
nificantly increased cell densities of CD45+ cells
(Fig. 3B; P = 0.019), CD3+ cells (Fig. 3F; P = 0.035),
and CD8+ cells (Fig. 3J; P = 0.003) in tumor nests as
well. Next, we analyzed LN metastases in terms of NE
subtypes and immune cell distribution, where we
found a significantly increased density of CD45+,
CD3+, and CD8+ cells in NE-low compared to NE-
high LN metastases in tumor nests (Fig. 3B,F,J), but
not in the stroma (Fig. 3A,E,I). Figure 3C,D,G,H
show the relative immune cell distributions according
to NE subtypes, where CD3/CD45 and CD8/CD3
ratios were significantly increased in NE-low (vs NE-
high), tumors (P < 0.05) in tumor nests, but not in
stroma. Figure 3K shows a representative sample of
NE-low SCLC subtype stained with CD45, where mas-
sive infiltration of stroma and a relatively high number
of immune cells in tumor nests are characteristic. On
the contrary, a typical ‘immune desert’ or infiltrate-ex-
cluded phenotype with scattered CD45+ cells both in
Fig. 2. Immune cell distribution in primary SCLC tumors and matched LN metastases according to stroma and tumor nests. Significantly
higher cell density was determined in the stroma of LN metastases compared to primary tumors, for CD45 (893.1  159.4 vs
1993  426.6 cellmm2, P = 0.049, n = 59, A), CD3 (258.5  56.47 vs 585.4  132.2 cellmm2, P = 0.033, n = 56, E), but not for CD8
(165.9  38.46 vs 356.0  80.07 cellmm2, P = 0.075, n = 58, I). Immune cell density showed no significant difference in tumor nests
(tumor) in LN metastases compared to primary tumors, for CD45 (61.52  13.21 vs 107.9  26.25 cellmm2, P = 0,215,, n = 59, B), CD3
(17.13  4.62 vs 39.50  13.13 cellmm2, P = 0.251, n = 56, F), and CD8 (8.66  2.78 vs 21.62  9.295 cellmm2, P = 0.332, n = 58, J).
Moreover, the stroma of primary tumors are significantly more infiltrated by major immune cells vs tumor nests, for CD45 (893.1  159.4
vs 61.52  13.21 cellmm2, P < 0.001, n = 31, C), CD3 (258.5  56.47 vs 17.13  4.62 cellmm2, P < 0.001, n = 29, G), and CD8
(165.9  38.46 vs 8.67  2.78 cellmm2, P < 0.001, n = 30, K). The stroma of LN metastases are significantly more infiltrated by major
immune cells vs tumor nests, for CD45 (1993  426.6 vs 107.9  26.25 cellmm2, P < 0.001, n = 28, D), CD3 (585.4  132.2 vs
39.50  13.13 cellmm2, P = 0.002, n = 26, H), and CD8 (356.0  80.07 vs 21.62  9.295 cellmm2, P < 0.001, n = 28, L). Wilcoxon
matched-pair test was used to compare immune cell densities in the stromal vs intratumoral compartments. Mann–Whitney U-test
was used to compare immune cell densities in the stroma and tumor compartments of primary tumors vs LN metastases. Metric data
were shown as mean and corresponding SEM, and graphs indicate the mean and corresponding 95% CI. Statistical significance *P < 0.05;
**P < 0.01.
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Fig. 3. Immune cell distribution in primary SCLC tumors and matched LN metastases according to stroma and tumor nests based on NE
tumor subtypes. Stained specimens revealed increased CD45+ cell densities in NE-low primary tumor subtypes compared to NE-high ones
including both stroma (1371  300.5 vs 627.5  156.8 cellmm2, respectively, P = 0.02, n = 31, A) and tumor nests (tumor;
106.2  26,67 vs 39,17  12.04 cellmm2, respectively, P = 0.019, n = 31, B). We found a significantly increased density of CD45+ cells in
NE-low LN metastases compared to NE-high subtypes in tumor nests (221.0  7.06 vs 73.95  20.86 cellmm2, respectively, P = 0.035,
n = 28, B) but not in stroma (2436  668.1 vs 1845  527.7 cellmm2, respectively, P = 0.071, n = 28, A). There were significantly
increased densities of CD3+ cells in NE-low primary tumor compared to NE-high subtypes in stroma (423.7  103 vs
166.8  58.09 cellmm2, respectively, P = 0.022, n = 29, E) and in tumor nests (33.22  10.89 vs 9.08  3.11 cellmm2, respectively,
P = 0.035, n = 29, F). We found a significantly increased density of CD3+ cells in NE-low LN metastases compared to NE-high subtypes in
tumor nests (84.67  41.47 vs 25.95  10.83, P = 0.032, n = 26, F) but not in stroma (721.9  160.4 vs 539.9  168.8, P = 0.527, n = 26,
E). There were significantly increased densities of CD8+ cells in NE-low primary tumor compared to NE-high subtypes both in stroma
(307.5  77.11 vs 87.28  29.77 cellmm2, P = 0.006, n = 30, I) and in tumor nests (20.56  6.11 vs 2.72  1.66, P = 0.003, n = 30, J).
We found a significantly increased density of CD8+ cells in NE-low LN metastases compared to NE-high subtypes in tumor nests
(66.17  34.30 vs 8.25  3.76 cellmm2, respectively, P = 0.006, n = 28, J) but not in stroma (469.4  117.6 vs
318.2  99.36 cellmm2, respectively, P = 0.063, n = 28, I). According to NE-low and NE-high primary tumors the CD3+/CD45+ cell ratio
was limited to 29.55  2.25 % and 20.78  3.67% (P = 0.14) in the stroma, and 32.07  3.84% and 15.86  3.88% (P = 0.016) in tumor
nests (C, D). According to NE-low and NE-high primary tumors, the CD8+/CD3+ cell ratio was limited to 68.6  4.84% and 50.33  5.14%
(P = 0.022) in the stroma and 65.21  6.79% and 29.14  13.4% (P = 0.033) in tumor nests, respectively (G, H). According to NE-low and
NE-high LN metastases the CD8+/CD3+ cell ratio was limited to 63.14  2.14% and 50.89  5.11% (P = 0.16) in the stroma and
69  4.41% and 31.27  4.54%, P < 0.001 in tumor nests, respectively (G, H). CD45 immunolabeling on a representative section of NE-
low (K) LN metastasis shows highly infiltrated stroma and tumor nests, whereas tumor-infiltrating immune cells are absent both in the
stroma and in the tumor nests on the sample of NE-high primary tumor (L). Mann–Whitney U-test was used to compare immune cell
densities in the stroma and tumor compartments in NE-high vs NE-low primary tumors and LN metastases. Student’s t-test was used to
compare CD3/CD45 and CD8/CD3 cell density ratios in NE-high vs NE-low primary tumors and LN metastases. Metric data were shown as
mean and corresponding SEM, and graphs indicate the mean and corresponding 95% CI. Statistical significance *P < 0.05; **P < 0.01.
1953Molecular Oncology 14 (2020) 1947–1965 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
D. Dora et al. Immune microenvironment in NE-high vs NE-low SCLC
stroma and in tumor nests is shown in Fig. 3L from a
representative sample of NE-high SCLC tumor sub-
type.
3.3. Immune checkpoint expression and NE
subtypes
The expression pattern of emerging immune check-
points PVR and IDO in primary tumors and LN
metastases according to NE-high vs NE-low tumors is
shown in Fig. 4. IHC shows that PVR is expressed by
tumor cells, but not by stromal cells in both NE SCLC
subtypes (Fig. 4A,B). IDO is expressed by endothelial
cells (Fig. 4D) and stromal cells of various morphol-
ogy (Fig. 4C), just as by immune cells in tumor nests
(Fig. 4E) in both NE SCLC subtypes. PVR expression
showed no significant difference in primary tumors vs
LN metastases (Fig. 4F). However, in NE-low
Fig. 4. Distribution pattern of immune checkpoint PVR and IDO expression. PVR is expressed by tumor cells, but is not present in stromata
including both NE SCLC subtypes (A, B). IDO is expressed by endothelial cells (D), stromal cells of various morphology (C), and by immune
cells in tumor nests (E) in both NE SCLC subtypes. PVR expression showed no significant difference in primary tumor vs LN metastases
(1.45  0.22 vs 1.21  0.22, P = 0.425, n = 50, F), but a significantly higher expression in NE-low vs NE-high was found both in primary
tumors (2.11  0.3 vs 1.03  0.26, P = 0.024, n = 27, J) and LN metastases (1.83  0.47 vs 0.69  0.2, P = 0.032, n = 23, J). There were
no significant differences between primary tumors and LN metastases regarding the IDO expression in stroma endothelial (8.78  2.09 vs
8.83  3.61, P = 0.248, n = 48, G) and nonendothelial cells (16.02  3.26 vs 24.79  9.68, P = 0.541, n = 48, H), whereas the intratumoral
expression of IDO was significantly higher in LN metastases compared to primary tumors (3.17  1.09 vs 24.79  9.68, P = 0.023, n = 47,
I). IDO stroma endothelium and nonendothelial cell expression showed no significant difference according to NE-low and NE-high tumor
subtypes including primary tumors (11.75  3.18 vs 7.56  3.49, P = 0.121, n = 26, K and 21.81  5.34 vs 12.93  4, P = 0.256, n = 26,
L) and LN metastases (10.20  5.39 vs 8.47  4.4, P = 0.196, n = 22, K; and 45.60  34.66 vs 19.32  8.55, P = 0.172, n = 22, L). In
contrast, the intratumoral expression of IDO was significantly higher in NE-low primary tumors (vs NE-high tumors; 7.31  2.15 vs
1.3  0.65, P = 0.041, n = 26, M), but not in LN metastases (45.60  34.66 vs 19.32  8.55, P = 0.172, n = 21, M). Mann–Whitney U-test
was used to compare PVR and IDO expression in primary tumors vs LN metastases and in NE-high vs NE-low primary tumors and LN
metastases. Metric data were shown as mean and corresponding SEM, and graphs indicate the mean and corresponding 95% CI.
Statistical significance *P < 0.05.
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subtype, a significantly higher expression was found
compared in the NE-high subtype both in primary
tumors (P = 0.024) and in LN metastases (P = 0.032;
Fig. 4J).
There were no significant differences in IDO expres-
sion of stroma endothelial (Fig. 4G) and nonendothe-
lial cells (Fig. 4H) between primary tumors and LN
metastases. In contrast, intratumoral expression of
IDO was higher by orders of magnitude in LN metas-
tases compared to primary tumors (P = 0.023;
Fig. 4I). We also assessed IDO expression in different
NE phenotypes. IDO stroma endothelium and nonen-
dothelial cell expression showed no significant differ-
ence between NE-low and NE-high tumor subtypes
neither in primary tumors nor in LN metastases
(Fig. 4K,L). On the contrary, intratumoral expression
of IDO was significantly higher in NE-low (vs NE-
high) primary tumors (P = 0.041), but not in LN
metastases (Fig. 4M).
Next, we investigated the associations between the
expression of immune checkpoints and immune cell
infiltration (Table 1), where we found a significantly
strong positive correlation between IDO stroma
endothelium, stroma nonendothelial cell, and immune
cell density in stroma including CD45+ cells (Fig. 5A,
B) and CD8+ T cells (Fig. 5D,E) in primary tumors.
Furthermore, there was a statistically significant strong
positive correlation between primary tumor IDO
expression and immune cell density in tumor nests,
including CD45+ cells (Fig. 5C), and CD8+ T cells
(Fig. 5F). In terms of LN metastases, we found a sta-
tistically significant strong positive correlation between
IDO stroma endothelium, stroma nonendothelial cell,
and stromal CD45+ cell density (Fig. 5G,H) and a sig-
nificant moderate positive correlation between IDO
stroma endothelium, stroma nonendothelial cell, and
stromal CD8+ T-cell density (Fig. 5J,K). Moreover,
there was a statistically significant strong positive cor-
relation between IDO expression and immune cell den-
sity in tumor nests including CD45+ cells (Fig. 5I) and
CD8+ T cells (Fig. 5L). Plot charts of statistically sig-
nificant correlations between PVR expression and
immune cell density are shown in Fig. S3.
3.4. Expressional analysis of MHC II protein and
T-cell exhaustion markers TIM3, PD1, and LAG3
In our analysis, we performed immunostainings and
in situ expression-based scoring of MHC II molecule,
pivotal in antigen presentation and immunological
crosstalk in the tumor microenvironment [27]. Stain-
ings on representative tissue samples show strong
MHC II expression in the majority of SCLC tumors.
Interestingly, apart from immune cells in the stroma
and tumor compartments, MHCII is also expressed on
cancer cells of tumor nests, especially in NE-low
tumors (Fig. 6A–E). Of note, in certain samples,
tumor cells showed diffuse expression of MHC II
(Fig. 6B), in some tumors the molecule occurred exclu-
sively on clusters of cancer cells, scattered in tumor
nests (Fig. 6A,C,D). Although there was no significant
difference in the immune cell expression of MHC II
between NE-low and NE-high tumors (Fig. 6H, tumor
cells showed significantly higher MHC II expression in
NE-low compared to NE-high primary tumors
(P = 0.004; Fig. 6I).
Next, we evaluated the extent of lymphocyte exhaus-
tion in SCLC. We performed IHC with antibodies
against TIM3, PD1, and LAG3 molecules. None of
the tissue samples of our 32 patients’ cohort (neither
primary tumors nor LN metastases) displayed positiv-
ity for PD1 or LAG3. On the contrary, TIM3 expres-
sion was present on lymphocytes of stromal bands and
tumor nests as well (Fig. 6E,F). Both stromal expres-
sion and intratumoral expression of TIM3 were signifi-
cantly higher in NE-low vs NE-high primary tumors
(P = 0.025 and P = 0.015, respectively), but not in LN
metastases (Fig. 6J,K). Of note, the absolute number
of TIM3-positive cells in each sample was considerably
higher in LN metastases compared to primary tumors
(Fig. 6J,K). PD-L1 protein expression was not found
in any of the samples (data not shown).
4. Discussion
The standard of care therapy for extensive-stage SCLC
now includes immunotherapy in the front-line setting.
The addition of atezolizumab or durvalumab to
chemotherapy has changed practice recently and is
associated with a moderate significantly longer PFS
and OS than chemotherapy on its own [1,2]. However,
as of yet, no predictive biomarkers have been identi-
fied, and the PFS curves seem to overlap during the
initial 8 months, showing that most patients do not
benefit from immunotherapy. Additionally, there were
increased OS benefits for selected patients that might
respond to immunotherapy.
Recent advancements in transcriptomics studies
highlight the potential of a distinct microenvironment
in SCLC NE subtypes. Understanding the immunol-
ogy of NE subtypes might affect the clinical outcome
and help lay the framework for immunotherapy
administration in this devastating cancer [6–8]. How-
ever, to date, studies have been performed exclusively
on NSCLC samples. Therefore, our study aims to fill
this gap of knowledge with a detailed IHC analysis of
1955Molecular Oncology 14 (2020) 1947–1965 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
D. Dora et al. Immune microenvironment in NE-high vs NE-low SCLC
T
a
b
le
1
.
C
o
rr
e
la
ti
o
n
o
f
im
m
u
n
e
c
h
e
c
k
p
o
in
ts
e
x
p
re
s
s
io
n
a
n
d
im
m
u
n
e
c
e
ll
in
fi
lt
ra
ti
o
n
.
n
:
n
u
m
b
e
r
o
f
p
a
ti
e
n
ts
;
r:
C
o
rr
e
la
ti
o
n
C
o
e
ffi
c
ie
n
t;
P
:
p
ro
b
a
b
ili
ty
v
a
lu
e
;
P
ri
m
a
ry
:
p
ri
m
a
ry
tu
m
o
r;
S
tr
o
m
a
:
tu
m
o
r
s
tr
o
m
a
a
re
a
;
T
u
m
o
r:
tu
m
o
r
n
e
s
t
in
c
lu
d
in
g
in
tr
a
tu
m
o
ra
l
a
re
a
.
P
ri
m
a
ry
tu
m
o
r
c
e
ll
d
e
n
s
it
y
(c
e
llm
m

2
)
L
N
m
e
ta
s
ta
s
is
c
e
ll
d
e
n
s
it
y
(c
e
llm
m

2
)
C
D
4
5
+
C
D
3
+
C
D
8
+
C
D
4
5
+
C
D
3
+
C
D
8
+
S
tr
o
m
a
T
u
m
o
r
S
tr
o
m
a
T
u
m
o
r
S
tr
o
m
a
T
u
m
o
r
S
tr
o
m
a
T
u
m
o
r
S
tr
o
m
a
T
u
m
o
r
S
tr
o
m
a
T
u
m
o
r
P
ri
m
a
ry
P
V
R
e
x
p
re
s
s
io
n
r
0
.3
9
9
a
0
.5
2
9
b
0
.3
6
0
a
0
.4
2
6
a
0
.4
0
6
a
0
.5
0
0
b
0
.2
5
0
.1
2
0
.3
4
0
.2
0
0
.3
0
0
.2
1
P
0
.0
1
2
0
.0
0
1
0
.0
2
4
0
.0
1
1
0
.0
1
1
0
.0
0
4
0
.3
2
0
0
.6
4
0
0
.1
5
9
0
.4
2
1
0
.2
1
9
0
.4
1
3
n
2
4
2
4
2
4
2
4
2
4
2
4
1
8
1
8
1
9
1
8
1
9
1
8
ID
O
s
tr
o
m
a
e
n
d
o
th
e
liu
m
r
0
.7
8
2
b
0
.8
7
0
b
0
.8
5
1
b
0
.9
0
7
b
0
.8
7
2
b
0
.7
9
7
b
0
.2
5
0
.0
4
0
.0
7
0
.0
1
0
.0
3
0
.0
4
P
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.3
0
9
0
.8
6
5
0
.7
5
4
0
.9
5
6
0
.9
0
4
0
.8
7
8
n
2
3
2
3
2
3
2
3
2
3
2
3
1
9
1
8
2
0
1
8
2
0
1
8
ID
O
s
tr
o
m
a
n
o
n
e
n
d
o
th
e
lia
l
c
e
ll
r
0
.7
0
2
b
0
.7
7
0
b
0
.7
5
7
b
0
.7
9
0
b
0
.7
7
2
b
0
.6
9
7
b
0
.2
2
0
.0
6
0
.0
3
0
.0
1
0
.0
2
0
.1
0
P
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.3
6
7
0
.8
1
7
0
.8
9
9
0
.9
5
4
0
.9
1
9
0
.6
8
6
n
2
3
2
3
2
3
2
3
2
3
2
3
1
9
1
8
2
0
1
8
2
0
1
8
ID
O
tu
m
o
r
r
0
.7
2
2
b
0
.7
9
6
b
0
.7
6
7
b
0
.8
2
9
b
0
.8
1
2
b
0
.8
0
1
b
0
.0
4
0
.2
4
0
.1
2
0
.3
3
0
.1
6
0
.2
9
P
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.0
0
0
0
.8
5
8
0
.3
3
9
0
.6
0
6
0
.1
8
0
0
.4
9
1
0
.2
5
2
n
2
3
2
3
2
3
2
3
2
3
2
3
1
9
1
8
2
0
1
8
2
0
1
8
L
N
P
V
R
e
x
p
re
s
s
io
n
r
0
.1
0
0
.0
3
0
.1
2
0
.1
0
0
.1
2
0
.2
5
0
.5
2
7
b
0
.5
0
7
b
0
.3
5
5
a
0
.5
4
3
b
0
.3
0
0
.5
2
1
b
P
0
.6
1
9
0
.9
0
1
0
.5
7
0
0
.6
3
8
0
.5
5
8
0
.2
3
4
0
.0
0
2
0
.0
0
3
0
.0
3
5
0
.0
0
2
0
.0
7
6
0
.0
0
4
n
2
5
2
4
2
5
2
4
2
5
2
4
2
2
2
2
2
2
2
2
2
2
2
2
ID
O
s
tr
o
m
a
e
n
d
o
th
e
liu
m
r
0
.3
9
0
.0
8
0
.2
0
0
.0
9
0
.1
7
0
.0
7
0
.8
0
6
b
0
.6
4
1
b
0
.4
5
0
a
0
.5
1
5
a
0
.5
4
2
b
0
.5
2
3
a
P
0
.0
6
2
0
.7
2
0
0
.3
4
1
0
.6
7
1
0
.4
1
5
0
.7
6
2
0
.0
0
0
0
.0
0
1
0
.0
3
1
0
.0
1
2
0
.0
0
6
0
.0
1
0
n
2
4
2
3
2
4
2
3
2
4
2
3
2
3
2
3
2
3
2
3
2
3
2
3
ID
O
s
tr
o
m
a
n
o
n
e
n
d
o
th
e
lia
l
c
e
ll
r
0
.2
2
0
.0
6
0
.0
9
0
.1
0
0
.0
2
0
.1
7
0
.8
0
1
b
0
.7
7
9
b
0
.6
3
6
b
0
.6
6
5
b
0
.6
8
1
b
0
.6
7
9
b
P
0
.2
9
9
0
.7
7
2
0
.6
8
6
0
.6
3
4
0
.9
1
4
0
.4
3
2
0
.0
0
0
0
.0
0
0
0
.0
0
3
0
.0
0
1
0
.0
0
0
0
.0
0
0
n
2
4
2
3
2
4
2
3
2
4
2
3
2
3
2
3
2
3
2
3
2
3
2
3
ID
O
tu
m
o
r
r
0
.2
2
0
.0
1
0
.0
6
0
.1
9
0
.0
5
0
.0
5
0
.6
6
1
b
0
.6
8
9
b
0
.3
0
0
.5
5
8
b
0
.4
0
0
.5
8
1
b
P
0
.3
0
6
0
.9
8
1
0
.7
7
6
0
.3
8
6
0
.8
0
9
0
.8
1
5
0
.0
0
1
0
.0
0
0
0
.1
7
1
0
.0
0
6
0
.0
5
3
0
.0
0
4
n
2
4
2
3
2
4
2
3
2
4
2
3
2
2
2
3
2
3
2
3
2
3
2
3
a
C
o
rr
e
la
ti
o
n
is
s
ig
n
ifi
c
a
n
t
a
t
th
e
0
.0
5
le
v
e
l
(t
w
o
-t
a
ile
d
S
p
e
a
rm
a
n
te
s
t)
.
b
C
o
rr
e
la
ti
o
n
is
s
ig
n
ifi
c
a
n
t
a
t
th
e
0
.0
1
le
v
e
l
(t
w
o
-t
a
ile
d
S
p
e
a
rm
a
n
te
s
t)
.
1956 Molecular Oncology 14 (2020) 1947–1965 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Immune microenvironment in NE-high vs NE-low SCLC D. Dora et al.
Fig. 5. Plot diagrams of significant moderate-to-strong correlations between immune checkpoints and immune cell infiltration. There was a
significant strong positive correlation between primary tumor IDO stroma endothelium, stroma nonendothelial cell, and immune cell density
in stroma including CD45+ cells (r = 0.78 and r = 0.7, respectively, P < 0.001, A, B), and CD8+ T cells (r = 0.87 and r = 0.77, respectively,
P < 0.001, D, E). Similarly, there was a statistically significant strong positive correlation between primary tumor IDO intratumoral
expression and immune cell density in tumor nests, including CD45+ cells (r = 0.79, P < 0.001, C), and CD8+ T cells (r = 0.8, P < 0.001, F).
A statistically significant strong positive correlation was present between IDO stroma endothelium, stroma nonendothelial cell, and CD45+
cell density in the stroma of LN metastases (r = 0.8 and r = 0.8, respectively, P < 0.001, G, H). There was a significant moderate positive
correlation between IDO stroma endothelium (r = 0.54, P < 0.006) and CD8+ T-cell density and a strong positive correlation between stroma
nonendothelial cell and CD8+ T-cell density (r = 0.68, P = 0.001) in the stromata of LN metastases (J, K). Moreover, there was a statistically
significant strong positive correlation, between primary tumor IDO intratumoral expression and immune cell density in tumor nests,
including CD45+ cells (r = 0.68, P < 0.001, I), and a moderate positive correlation between the same parameters, regarding CD8+ T cells
(r = 0.58, P < 0.001, L). Spearman’s rank correlation was used for variables CD45, CD3, CD8, IDO, and Kendall’s Tau-b (Kendall rank
correlation coefficient) for ordinal variable PVR. Metric data were shown as mean and corresponding SEM, and graphs indicate the mean
and corresponding 95% CI.
1957Molecular Oncology 14 (2020) 1947–1965 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
D. Dora et al. Immune microenvironment in NE-high vs NE-low SCLC
1958 Molecular Oncology 14 (2020) 1947–1965 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Immune microenvironment in NE-high vs NE-low SCLC D. Dora et al.
immune cell populations on human SCLC tissue sam-
ples. We aim to provide an in-depth intertumor
heterogeneity array of IHC staining on primary
tumors vs matched LN metastases on immune cell
infiltration and immune activation of stroma and
epithelial tumor nests in NE-low and NE-high tumor
phenotypes. Importantly, to our knowledge, this is the
first human study delivering in situ proteomics data on
immune cell populations in LN metastases of SCLC
patients.
Our main findings from this study interpret the
proteomic profile of the tumor microenvironment to
further highlight the relevance of NE-low vs NE-
high tumor subtypes in the clinical setting. It is also
important to note that the presence of lymphatics-as-
sociated genes might influence any transcriptomic
study performed on LN metastases. Therefore, our
in situ proteomic analysis might overcome the limita-
tions above. Others showed that the extent of
immunological infiltration in tumor tissue and the
expression of immune checkpoints proved to be a
reliable marker for response to anti-PD-1
immunotherapy and long-term survival NSCLC [38],
and other malignancies, like breast cancer [39], mela-
noma [40], colorectal carcinoma [41], and prostatic
cancer [42] as well. Another group indicated on
NSCLC TMA samples that a high number of stro-
mal CD4+ and epithelial and stromal CD8+ cells
were independent positive prognostic markers, and
CD8+ tumor-infiltrating lymphocytes (TILs) can
stratify immunotherapy-treated patients of different
clinical outcome [43]. Furthermore, a low level of
CD8+ lymphocyte infiltration in tumor stroma was
positively correlated with an augmented incidence of
angiolymphatic tumor invasion [38].
In the current study, we first revealed that immune
cell infiltration both in primary tumors and in LN
metastases is predominant in loosely arranged stromal
bands, but not in tumor nests. Even in selected, rela-
tively highly infiltrated tumors, only about 7% in pri-
mary and 5% in LN metastasis of CD45+ cells and
5% and 6%, respectively, of CD8+ T cells are localized
in the close microenvironment of tumor cells (Fig. 2).
Furthermore, we established that the stroma of LN
metastases had significantly higher immune cell density
compared to primary tumors; however, this difference
was not significant in tumor nests (Fig. 2). Our analy-
ses demonstrated that both stromal and intratumoral
CD3+/CD45+ cell ratio is limited to 27% when pooling
both primary tumors and LN metastases (Fig. S2A).
This means that TILs make up only about one quarter
of all immune cells regardless of their anatomic
(macroscopic) localization (primary tumor vs LN).
Consequently, a significant fraction of CD45+ cells
belongs to populations of macrophages, DCs, neu-
trophils, or other nonspecific immune cells in SCLC.
In contrast to CD3+/CD45+ cell ratios, we found a sig-
nificant difference in CD8+/CD3+ cell ratio in stroma
vs tumor when both primary and LN metastases were
pooled, meaning tumor stroma has a significantly
higher ratio of effector T cells compared to tumor
nests (Fig. S2B).
The same TMA sets clustered NE-high and NE-low
SCLC subsets [34] based on the top RNA genes asso-
ciated with NE differentiation [9,44,45]. The latest pre-
clinical studies suggest that, compared to the NE-high,
Fig. 6. MHC II and lymphocyte exhaustion marker expression in SCLC. Qualitative in situ IHC data on representative primary tumor and LN
metastasis samples (ID of samples in italics) show strong expression of MHC II protein (A, B). MHC II is expressed in stromal (C arrows),
intratumoral immune cells (C asterisk), and in cancer cells of tumor nests similarly (C arrowhead). MHC II staining in tumor nests can be
diffuse (B), or mosaical (D encircled area, magnified inset from A). NE-low tumor shows strong expression of MHC II molecule on cancer
cells and on stromal and intratumoral immune cells (A–D), whereas NE-high tumor exhibits strong stromal MHC II expression on immune
cells, but not in tumor nests or cancer cells (E). TIM3 protein is expressed in stromal lymphocytes and scattered immune cells in tumor
nests of NE-low LN metastasis (F). In NE-high tumors, only a low number of TIM3+ cells occur sparsely in stromal brands (G). There were
no significant differences in immune cell expression (stromal and intratumoral pooled) of MHC II molecule between NE-low and NE-high
tumors neither in primary tumors (2.83  0.22 vs 2.29  0.19, P = 0.086, n = 30, H), nor in LN metastases (2.82  0.16 vs 2.45  0.19,
P = 0.289, n = 27, H). However, tumor cells show significantly stronger MCII expression in NE-low versus NE-high primary tumors
(2.11  0.45 vs 0.41  0.25, P = 0,004, n = 30, I), but not in LN metastases (1.5  0.67 vs 0.66  0.18, P = 0.298, n = 27, I). NE-low
tumors show significantly higher expression of TIM3 compared to NE-high tumors in the stroma of primary tumors (12.31  4.77 vs
4.07  2.48, P = 0.025, n = 29, J), but not in LN metastases (22.17  10.53 vs 33.9  12.24, P = 0.307, n = 27, J). In tumor nests
(tumor), expression of TIM3 is significantly higher in NE-low compared to NE-high primary tumors (2.87  1.15 vs 0.15  0.1, P = 0.015,
n = 29, K), but the same difference is not significant in LN metastases (4  2.48 vs 3.44  1.72, P = 0.905, n = 27, K). Mann–Whitney U-
test was used to compare MHC II and TIM3 expression in primary tumors vs LN metastases and in NE-high vs NE-low primary tumors and
LN metastases. Metric data were shown as mean and corresponding SEM, and graphs indicate the mean and corresponding 95% CI.
Statistical significance *P < 0.05; **P < 0.01.
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the NE-low subtype is more likely to respond to
immunotherapy due to its ‘immune oasis’ phenotype,
emphasizing the necessity and importance of molecular
and in situ immunological characterization before the
assessment of therapies to this type of recalcitrant can-
cer [9]. Therefore, we compared in situ the quantitative
and qualitative extent of the immunological microenvi-
ronment of SCLC tumors according to NE-low and
NE-high subtypes. In line with previously published
data, our results confirm that NE-low tumors are sig-
nificantly more infiltrated by immune cells, primarily
by CD8+ effector T cells [9]. Interestingly, in our
study, the CD3+/CD45+ cell ratio was not significantly
different in NE-low relative to NE-high tumors, sug-
gesting that the T-cell population is not predominant,
neither in stroma nor in tumor nests of NE-low
tumors. In contrast, a substantially higher percentage
of CD8-expressing lymphocytes are present both in
NE-low primary tumors and in LN metastases (vs
NE-high), and the difference is even more considerable
in tumor nests (Fig. 3).
Next, in order to identify targets and further under-
stand the immune microenvironment, we analyzed
expression of immune checkpoints. PVR (CD155) has
been reported to mediate T cell activation via CD226,
or impede T lymphocytes by binding to TIGIT. PVR
overexpression is associated with poor prognosis in
melanoma, colorectal, lung, and pancreatic cancers
[46–49]. Our data show that strong PVR expression
was significantly more frequent in NE-low vs NE-high
tumors, both in primary tumors and in LN metastases.
Although PVR overexpression was correlated with
poor prognosis in multiple studies [48,49], we found a
significant moderate positive correlation between PVR
expression and immune cell density in tumor nests
including CD45+ and CD8+ cells.
Another checkpoint, IDO, belonged to the group of
anticancer molecules based on its antipathogenic func-
tion [50]. Subsequent studies, however, identified tissue
macrophages producing high levels of IDO upon inter-
feron-gamma (IFN-c) stimulation inhibiting effector
T-cell proliferation [51]. IDO expression was reported
in lung cancer cell lines [52] and in situ in 42–43% of
NSCLC samples [53,54]. We found IDO expression on
stromal cells of various morphology. Of note, the pres-
ence of IDO in stroma endothelial cells is a novel find-
ing in SCLC. Previous studies showed that the
endothelial expression of IDO in metastatic kidney
cancer promotes response to immunotherapy and is
associated with better PFS [54]. In line with other
NSCLC studies, we observed scattered IDO immuno-
labeling only on tumor nest immune cells but not on
tumor cells [54]. The role of IDO was demonstrated in
other respiratory conditions as well, like pneumonia,
where inflammatory macrophages were identified as a
primary source of the molecule [56]. IDO expression
was not different in stromal cellular elements or
endothelium according to NE subtypes. However,
IDO expression in tumor nests showed significantly
higher levels in NE-low tumors. Consequently, estab-
lishing an immunosuppressive microenvironment for
TILs that might explain why NE-low tumors do not
unequivocally have better prognosis despite their ‘im-
mune oasis’ phenotype. Stroma IDO expression might
be associated with many types of inhibitory cells in the
immunosuppressive tumor microenvironment, like can-
cer-associated fibroblasts, myeloid-derived suppressor
cells, or tumor-associated macrophages, which requires
further confirmation. Interestingly, intratumoral
expression of IDO showed a conspicuous discrepancy
in LN metastases where IDO-positive cells were much
more abundant, than in primary tumors (Fig. 4I). Our
findings show that LN metastases are significantly
more infiltrated by immune cells (vs primary tumors).
This might result in clinically indifferent molecular
behavior and aggressiveness of LN metastases due to
their distinct immunological microenvironment and
immune checkpoint expression patterns. Moreover,
there was a statistically significant strong positive cor-
relation between intratumoral expression of IDO and
immune cell density in tumor nests including CD45+
cells (Fig. 5C) and CD8+ T cells (Fig. 5F). Our data
suggest that IDO overexpression is an escape mecha-
nism of tumor cells making immune cells and lympho-
cytes entering tumor nests anergic and unable to
launch an immune response against them.
In lung cancer, it was previously shown in cell lines
[57] and tissue samples that some tumor cells displayed
MHC II expression, mostly in the vicinity of TILs in
highly infiltrated tumors [58]. The latter fact suggests
that immune cell infiltration may induce MHC II
expression in tumor cells in a permissive microenviron-
ment. In our study, we also revealed that MHC II
molecules are expressed in situ on cancer cells of cer-
tain SCLC tumors, but predominantly in the NE-low
subtype (Fig. 6), whereas PD-1 and PD-L1 protein
expression was not detectable in situ in any of the
samples. This finding is similar to other researchers’
that reported a relatively low rate of PD-L1 expression
in SCLC up to 35.0% (with a very low cutoff point of
5% for PD-L1 positive/negative expression), which
was consistently lower than that in NSCLC [59]. This
difference can be explained by a variety of factors,
including tumor stage and assays used. We found no
expression of lymphocyte exhaustion marker LAG3 in
our study showing that LAG3 is not relevant in the
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SCLC microenvironment. In contrast, TIM3 was
expressed by significantly more TILs in NE-low com-
pared to NE-high tumors. Irrespective of NE subtypes,
TIM3 was more expressed in LN metastases compared
to primary tumors. In connection with the clinical rele-
vance of TIM3, recently it was reported that inhibition
of the TIM3-related molecular pathway promoted
anticancer immunity and increased IFN-c production
of T cells [60]. Immune checkpoints PD-1, TIM-3, and
LAG-3 were also shown to be upregulated in TILs of
hepatocellular carcinomas and may enhance T-cell
response to tumor antigens in a synergistic way [61].
Altogether, our results confirm that NE-low tumors
and LN metastases (regardless of NE phenotype) seem
to be more immunogenic, with higher immune check-
point and lymphocyte exhaustion molecule expression.
Limitations of this study include that it is a retro-
spective cross-sectional study with limited clinico-
pathological data available. The patient population is
unique in terms of the resected sample size and corre-
sponding LN availability; however, it is small even in
the light of the fact that matched tumor samples are
usually not available in the case of SCLC. Prognostic
data are limited, and our study may be influenced by
the differences in the administration of oncotherapy
including surgical techniques over a long period.
5. Conclusion
To our knowledge, this is the first human study that
demonstrates in situ that SCLC stroma is more infil-
trated by immune cells compared to tumor nests.
Additionally, NE-low tumors are more infiltrated by
immune cells compared to NE-high tumors. Therefore,
our results suggest that SCLC is classified into two dis-
tinct NE subtypes that may alter treatment outcomes.
Accordingly, we hypothesize that NE-low tumors have
a microenvironment potentially associated with
increased benefit from immune checkpoint inhibitor
therapy. Consequently, patient NE subtype should be
identified in future clinical trials to select patients that
will most likely benefit from immunotherapy adminis-
tration. Moreover, PVR, IDO, MHCII, and TIM3 are
potential new targets in SCLC with increased expres-
sion in NE-low subtype, providing critical insight for
further prospective studies on SCLC immunotherapies.
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Fig. S1. Tumor nest and stroma area ratio in primary
SCLC tumors and matched LN metastases, according
to NE tumor subtypes. There were no significant dif-
ferences in stroma and tumor nest (tumor) area ratio
in primary tumors versus matched LN metastases
(0.84  0.23 vs 0.68  0.24, respectively, P = 0.22,
n = 59 A). No significant differences were present in
stroma and tumor area ratio in primary tumors and
LN metastases according to NE subtypes (primary
NE-low vs high: 0.62  0.14 vs 1.715  0.85,
P = 0.92, n = 31; LN NE-low vs high: 0.6915  0.25
vs 0.6878  0.3, respectively, P = 0.377, n = 28, B).
Fig. S2. Relative distribution of immune cells accord-
ing to primary SCLC tumors and matched LN metas-
tases. There was no significant difference in CD3+/
CD45+ cell ratio between stroma and tumor nests
when pooling both primary and LN metastases
(27.21  2.02 vs 26.06  2.85, respectively, P = 0.73,
A), but there was a significant difference in the case of
CD8+/CD3+ cell ratio (56.44  2.78 vs 45.76  4.91,
P = 0.044, B). There was no significant difference in
stromal CD3+/CD45+ cell ratio according to primary
tumors and LN metastases (24.15  2.86, vs
30.35  3.08, P = 0.147, C). We found no statistically
significant difference in CD3+/CD45+ cell ratio in
tumor nests according to primary tumors and LN
metastases (21.26  3.3 vs 29.9  4.87, P = 0.146, D).
There was no significant difference in CD8+/CD3+
ratio in stroma according to primary tumors and LN
metastases (58.88  3.98, vs 53.43  4.37, P = 0.361,
E). Similarly, no significant difference was identified in
CD8+/CD3+ ratio in tumor nests according to primary
tumors and LN metastases (47.18  8.78 vs
45.14  6.57, P = 0.854, F).
Fig. S3. Plot diagrams of significant moderate-to-
strong correlations between PVR and immune cell
densities in tumor nests. There were a statistically sig-
nificant moderate positive correlation between primary
tumor PVR expression and CD45+ (r = 0.52,
P = 0.001) and CD8+ (r = 0.5, P = 0.004) immune cell
densities in tumor nests (A and B). Furthermore, in
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terms of LN metastases, a similarly moderate signifi-
cant positive correlation was found between PVR
expression and immune cell densities in tumor nests,
including CD45+ (r = 0.507, P < 0.003), CD8+ cells
(r = 0.521, P < 0.004, C and D).
Table S1. Shows the summary of key protein expres-
sion data in the tumor microenvironment, according
to NE-low vs NE-high SCLC subtypes. Most impor-
tant mean-, SEM- and P-values.
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